NRx Pharmaceuticals, Inc.

NASDAQ:NRXP

Biotechnology

Healthcare
$2.55 +1.43%

+$0.06 today

Market cap
$113.04M
Beta
2.19
P/E (TTM)
-5.3
EPS (TTM)
-$0.76
52W Low $1.62High $5.06

Volume 1.39M

Average 1.27M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$14.11M

FY 2025 · Annual

Investing Cash Flow

-$2.81M

FY 2025 · Annual

Financing Cash Flow

$23.28M

FY 2025 · Annual

+211.0% YoY

Cash Flow Statement

USD
Metric
FY 2021
Dec 2021
FY 2022
Dec 2022
FY 2023
Dec 2023
FY 2024
Dec 2024
FY 2025
Dec 2025
Net Income(93.06M)(39.75M)(30.15M)(25.13M)(28.62M)
Depreciation & Amortization2K4K5K5K143K
Deferred Income Tax00000
Stock-Based Compensation7.79M3.63M387K486K228K
Change in Working Capital(4.9M)699K5.16M5.29M1.41M
Accounts Receivables831K00048K
Inventory00000
Accounts Payables(19K)(1.61M)2.66M(5.22M)113K
Other Working Capital(5.71M)2.31M2.51M10.51M1.25M
Other Non-Cash Items52.47M(4.33M)2.94M8.71M12.73M
Operating Cash Flow(37.7M)(39.76M)(21.66M)(10.64M)(14.11M)
Capital Expenditures(7K)(10K)(3K)00
Acquisitions (Net)0000(2.38M)
Purchases of Investments0000(432K)
Sales of Investments00000
Other Investing Activities00000
Investing Cash Flow(7K)(10K)(3K)0(2.81M)
Debt Repayment(1.28M)9.5M(3.09M)(1.5M)7.42M
Common Stock Issued36.98M22.7M8.12M5.91M15.86M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities27.75M10K03.07M0
Financing Cash Flow63.46M32.21M6.2M7.49M23.28M
Effect of Forex Changes00000
Net Change in Cash25.75M(7.55M)(15.46M)(3.15M)6.35M
Free Cash Flow(37.71M)(39.77M)(21.66M)(10.64M)(14.11M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$28.6M
+ D&A$143.0K
+ Stock-Based Comp$228.0K
+ Deferred Tax$0
+ Working Capital$1.4M
+ Other Non-Cash$12.7M
= Operating Cash Flow-$14.1M
- Capex$0
= Free Cash Flow-$14.1M

Analysis

FY2025 free cash flow is -$14.1M. FCF conversion is 49.3% of net income. Operating cash flow was -$14.1M, with capex of $0. The largest bridge item is Other Non-Cash at $12.7M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
DEF 14ADEF 14A filingNov 5, 2026
DEFA14ADEFA14A filingNov 5, 2026
4Statement of changes in beneficial ownershipNov 4, 2026
4Statement of changes in beneficial ownershipNov 4, 2026
8-KCurrent reportNov 2, 2026

Does NRXP generate free cash flow?

NRx Pharmaceuticals, Inc. (NRXP) generated -$14.11M of free cash flow in fiscal 2025.

How much operating cash flow does NRXP produce?

Operating cash flow was -$14.11M, before capital expenditures of $0.00.